Jazz Pharmaceuticals plc (JAZZ) Financials
Annual revenue, profitability and per-share results for Jazz Pharmaceuticals plc, as reported in SEC filings.
Revenue • FY2025
$4.27B
▲ 4.9%YoY
Net income • FY2025
-$356.15M
▼ 163.6%YoY
Diluted EPS • FY2025
-$5.84
▼ 167.5%YoY
Annual income statement
| Period | Revenue | Net income | Gross profit | Dil. EPS | Free cash flow | Op. margin | Rev. growth |
|---|---|---|---|---|---|---|---|
| FY2025 | $4.27B | -$356.15M | — | -$5.84 | $1.3B | -10.1% | +4.9% |
| FY2024 | $4.07B | $560.12M | — | $8.65 | $1.36B | 17.6% | +6.1% |
| FY2023 | $3.83B | $414.83M | — | $6.10 | $1.07B | 15.1% | +4.8% |
| FY2022 | $3.66B | -$224.06M | — | -$3.58 | $1.24B | -1.8% | +18.3% |
Figures as reported in Jazz Pharmaceuticals plc's 10-K filings on SEC EDGAR. Fiscal years may differ from calendar years.
Never miss a JAZZ filing.
Get an email when JAZZ files its next 8-K, Form 4, 10-K or 10-Q with the SEC. Free, no account needed.
Free foreverNo account requiredOne-click unsubscribe
Source: SEC EDGAR.